Elsevier

The Ocular Surface

Volume 13, Issue 2, April 2015, Pages 118-132
The Ocular Surface

Clinical Practice
Clinical Guidelines for Management of Dry Eye Associated with Sjögren Disease

https://doi.org/10.1016/j.jtos.2014.12.001Get rights and content

Abstract

Purpose

To provide a consensus clinical guideline for management of dry eye disease associated with Sjögren disease by evaluating published treatments and recommending management options.

Design

Consensus panel evaluation of reported treatments for dry eye disease.

Methods

Using the 2007 Report of the International Workshop on Dry Eye (DEWS) as a starting point, a panel of eye care providers and consultants evaluated peer-reviewed publications and developed recommendations for evaluation and management of dry eye disease associated with Sjögren disease. Publications were graded according to the American Academy of Ophthalmology Preferred Practice Pattern guidelines for level of evidence. Strength of recommendation was according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines.

Results

The recommendations of the panel are briefly summarized herein. Evaluation should include symptoms of both discomfort and visual disturbance as well as determination of the relative contribution of aqueous production deficiency and evaporative loss of tear volume. Objective parameters of tear film stability, tear osmolarity, degree of lid margin disease, and ocular surface damage should be used to stage severity of dry eye disease to assist in selecting appropriate treatment options. Patient education with regard to the nature of the problem, aggravating factors, and goals of treatment is critical to successful management. Tear supplementation and stabilization, control of inflammation of the lacrimal glands and ocular surface, and possible stimulation of tear production are treatment options that are used according to the character and severity of dry eye disease.

Summary

Management guidelines for dry eye associated with Sjögren’s disease are presented.

Introduction

The Sjögren’s Syndrome Foundation initiated development of clinical guideline recommendations for medical practitioners in 2010. Representatives from rheumatology, oral medicine/dentistry, and eye care providers were enlisted to evaluate recent literature and develop recommendations for those guidelines. This preliminary perspective from the eye care subcommittee is provided prior to the ultimate publication of the entire committee and is based upon agreement of the subcommittee members, all of whom contributed to the guidelines and agreed upon the recommendations.

The definition of dry eye provided by the 2007 International Dry Eye Workshop (DEWS) report is: “Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.”1

An alternative description of the disease is “dysfunctional tear syndrome” to emphasize that the tear film dysfunction can occur in the presence of normal tear secretion.2 The discomfort is often described in various ways, such as burning, stinging, grittiness or sensation of something in the eye (foreign body sensation), itching, and, occasionally, pain. A recent survey of the members of the Sjögren’s Syndrome Foundation revealed that the symptoms of dry eye were the most annoying and activity-limiting aspect of Sjögren disease. Sjögren disease is an autoimmune disease affecting primarily the exocrine glands of mucous membranes, resulting in dry eye and dry mouth, but often with additional musculoskeletal disturbance and damage to other body systems.3 Visual disturbance is often noted as fluctuation of vision, particularly during reading or working at a computer, and blinking often clears the vision.

Dry eye is usually classified into two major categories: aqueous-deficient dry eye, in which tear production is reduced, and evaporative dry eye, in which the evaporation of the tear film is abnormally high.1 Both categories have increased concentration of tear film constituents, as manifested by elevated osmolarity and rapid tear film breakup time (TFBUT).4, 5, 6, 7 Although the mechanisms of production of dry eye are easily separated, both conditions often occur simultaneously.

Inflammation of the lacrimal gland and ocular surface occur both as an inciting event in many cases and as a secondary effect as the dry eye disease worsens, prompting the name as keratoconjunctivitis sicca (KCS). Further classification of aqueous-deficient dry eye specifies dry eye that is associated with Sjögren disease versus dry eye not associated with Sjögren disease; this is done in recognition of the greater severity of aqueous-deficient dry eye as well as the greater inflammation associated with Sjögren disease.1, 8 It should be noted, however, that aqueous-deficient dry eye and evaporative dry eye have both been associated with Sjögren disease.9, 10

An additional approach to categorizing dry eye, which has become more frequently used in determining the management strategy, involves the gradation of severity of the dry eye based upon level of discomfort, interference with activities of daily living, degree of clinically observable inflammation, and response to previous therapy.11

The literature evaluating the management of dry eye specifically in Sjögren disease is limited, and the options for therapy most often are evaluated in non-Sjögren patients. In this review, the studies that specifically included Sjögren disease patients are identified, although the management options evaluated in non-Sjögren patients are presented when considered essential or helpful in management of Sjögren dry eye disease. Publications were graded according to the American Academy of Ophthalmology Preferred Practice Pattern guidelines for level of evidence (Table 1).

Eye care practitioners frequently encounter patients with dry eye symptoms, as there are more than an estimated 20 million people with dry eye in the United States.1 Although most patients complaining of dry eye disease do not have Sjögren disease, it is incumbent upon the practitioner to consider Sjögren disease when features of the dry eye suggest it as a possible etiology. More severe disease and more severe inflammation or difficulty in controlling the dry eye should prompt questions about concurrent dry mouth, arthritis, or other systemic evidence of inflammation or autoimmune disease. Patients with these associations should be referred to a dentist and rheumatologist for oral and systemic disease diagnosis and management.

Section snippets

Symptoms

Dry eye is usually symptomatic, although recent studies demonstrate that more than 40% of subjects with clear objective evidence of dry eye disease are asymptomatic.12 The first diagnostic clue is often the patient’s report of either eye discomfort and/or fluctuating vision. Many questionnaires have been developed to assess symptoms of dry eye, but few have been validated as accurate for diagnosis or response to therapy.

Dry eye surveys have been used in a variety of ways in both clinical care

Management of Dry Eye

The management approach to dry eye disease has changed over the past 10 years, but several principles persist. Communication between the practitioner and the patient is critical to assure that the patient understands the disease, the aggravating factors, and the management strategy. Given the multiple contributing causes of dry eye and the expansion of therapy to include nutritional support and management of lid margin disease, in addition to topical therapy, the patient should consider therapy

Summary and Recommendations

Dry eye disease is one of the most quality-of-life and activity-limiting features of Sjögren disease. In a given patient, the clinician must determine whether the dry eye is due to inadequate production of tears, excess evaporation, or a combination of both mechanisms; success of treatment depends upon proper recognition and approach to therapy.

Evaluation of symptoms can be accomplished by use of a number of questionnaires to grade severity of symptoms. Practical considerations recommend use of

References (102)

  • A.H. Wander et al.

    Extending the duration of tear film protection in dry eye syndrome: review and retrospective case series study of the hydroxypropyl cellulose ophthalmic insert

    Ocul Surf

    (2009)
  • P. Marsh et al.

    Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren Syndrome

    Ophthalmology

    (1999)
  • A.M. Avunduk et al.

    The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study

    Am J Ophthalmol

    (2003)
  • H.K. Lee et al.

    Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients

    Ophthalmology

    (2006)
  • D. Stevenson et al.

    Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group

    Ophthalmology

    (2000)
  • K. Sall et al.

    Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group

    Ophthalmology

    (2000)
  • L.D. Barber et al.

    Phase 3 safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years

    Ophthalmology

    (2005)
  • E.S. Rosenberg et al.

    Essential fatty acids in the treatment of dry eye

    Ocul Surf

    (2010)
  • M. Ono et al.

    Therapeutic effect of cevimeline on dry eye in patients with Sjögren’s syndrome: A randomized, double-blind clinical study

    Am J Ophthalmol

    (2004)
  • C.H. Dohlman

    Punctal occlusion in keratoconjunctivitis sicca

    Ophthalmology

    (1978)
  • A.W. Tuberville et al.

    Punctal occlusion in tear deficiency syndrome

    Ophthalmology

    (1982)
  • E. Goto et al.

    Improved functional visual acuity after punctal occlusion in dry eye patients

    Am J Ophthalmol

    (2003)
  • T. Kojima et al.

    The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study

    Am J Ophthalmol

    (2005)
  • T. Romero-Rangel et al.

    Gas-permeable scleral contact lens therapy in ocular surface disease

    Am J Ophthalmol

    (2000)
  • D. Finis et al.

    Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial

    Ocul Surf

    (2014)
  • The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007)

    Ocul Surf

    (2007)
  • A. Behrens et al.

    Dysfunctional tear syndrome. A Delphi approach to treatment recommendations

    Cornea

    (2006)
  • A.I. Grayzel

    What is Sjogren’s? Chapter 2

  • A. Tomlinson et al.

    Tear film osmolarity: determination of a referent for dry eye diagnosis

    Invest Ophthalmol Vis Sci

    (2006)
  • S.C. Pflugfelder et al.

    Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren’s syndrome keratoconjunctivitis sicca

    Curr Eye Res

    (1999)
  • R.L. Farris et al.

    Tear osmolarity variation in the dry eye

    Trans Am Ophthalmol Soc

    (1986)
  • Management and therapy of dry eye disease: report of the Subcommittee on Management and Therapy of Dry Eye Disease

    Ocul Surf

    (2007)
  • B.D. Sullivan et al.

    Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications

    Acta Ophthalmol

    (2014)
  • The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007)

    Ocul Surf

    (2007)
  • D.A. Schaumberg et al.

    Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies

    Arch Ophthalmol

    (2009)
  • N.L. Oden et al.

    Sensitivity and specificity of a screening questionnaire for dry eye

    Adv Exp Med Biol

    (1998)
  • Methodologies to diagnose and monitor dry eye disease: Report of the Diagnostic Methodologies Subcommittee of the International Dry Eye Workshop

    Ocul Surf

    (2007)
  • A. Gulati et al.

    The dry eye, Chapter 17

  • K.K. Nichols et al.

    International workshop on meibomian gland dysfunction: executive summary

    Invest Ophthalmol Vis Sci

    (2011)
  • B.D. Sullivan et al.

    An objective approach to dry eye disease severity

    Invest Ophthal Vis Sci

    (2010)
  • M.A. Lemp et al.

    Tear osmolarity in the diagnosis and management of dry eye disease

    Am J Ophthalmol

    (2011)
  • C.S. De Paiva et al.

    Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma

    Invest Ophthalmol Vis Sci

    (2007)
  • S.K. Chauhan et al.

    Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression

    J Immunol

    (2009)
  • S. Chotikavanich et al.

    Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome

    Invest Ophthalmol Vis Sci

    (2009)
  • R. Sambursky et al.

    Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye

    JAMA Ophthamol

    (2013)
  • T. Goto et al.

    Tear film stability analysis system: introducing a new application for videokeratography

    Cornea

    (2004)
  • C.S. de Paiva et al.

    Assessing the severity of keratitis sicca with videokeratoscopic indices

    Ophthalmology

    (2003)
  • K. Gumus et al.

    Non-invasive assessment of the tear film stability in patients with tear dysfunction using the Tear Film Stability Analysis System (TSAS)

    Invest Ophthalmol Vis Sci

    (2011)
  • S.L. Forstot et al.

    Management of dry eye, Chapter 21

  • G.N. Foulks

    Treatment of dry eye disease by the non-ophthalmologist

    Rheum Dis Clin N Am

    (2008)
  • Cited by (176)

    • Therapeutic Hyper-CL soft contact lens in Sjögren's syndrome

      2022, American Journal of Ophthalmology Case Reports
    View all citing articles on Scopus

    Funding support: The Sjogren’s Syndrome Foundation organized site meetings of the Committee for Ocular Clinical Guidelines in the Management of Dry Eye Associated with Sjogren Syndrome. No compensation was paid to any author.

    Financial disclosures: All participating authors completed Conflict of Interest forms of the American College of Rheumatology, a co-sponsor of the Sjogren Syndrome Clinical Guidelines project, and the ICMJE-AJO forms. Consultant or advisory positions (SLF, GNF, MG, MAL, KKN, JDN, SCP, PA); speaker bureaus or lecture fees (SLF, PCD, MAL, KKN, SCP, JF, JMT, PA); grant support (MG, KKN, SCP, PA); equity payments (GNF, MG, MAL, KKM, SCP); and expert witness testimony (JDN).

    Contributions of authors: Design and conduct of the panel (SLF, GNF, KH); collection, management, analysis, and interpretation of the data (SLF, GNF, PCD, MG, MAL, KKN, JDN, SCP, PA, DJ); and preparation, review, or approval of the manuscript (SLF, GNF, JF, PCD, MG, MAL, KKN, JDN, SCP, JMT, PA, DJ).

    Single-copy reprint requests to Gary N. Foulks, MD, FACS (address below).

    View full text